The “Improving Quality of Care in AD” report, commissioned and funded by Sanofi Genzyme & Regeneron and completed by KPMG, debuts at the annual meeting of the EADV. Changes to FDA regulations implemented as part of the CARES Act limit access to hydroquinone. This year’s Virtual Vegas Cosmetic Surgery and Aesthetic Dermatology conference features more than 72 hours of content over four days. Pfizer’s abrocitinib receives priority review designation from FDA for AD.
For eczema awareness month, the National Eczema Association (NEA) is offering virtual educational programs, community engagement activities, and additional free resources. Georgia, Oklahoma, and Texas have the highest rates of uninsurance. Zilxi minocycline topical foam launches as new data from the National Rosacea Society reveals an age gap in rosacea treatment approaches.
Dennis Porto, MD and Riyaz Farhaad, MD have launched AcneAlly.com, an online service that allows patients access to a board certified dermatologist and a standardized approach to assessment and long-term monitoring. Julie Harper, MD discusses findings from “Beyond the visible: Rosacea and psoriasis of the face;” the report supported by Galderma provides findings of a global survey involving over 600 patients with facial rosacea or psoriasis and 361 doctors across six countries. Dr. Shereene Idriss discusses Galderma’s “Face Up to Rosacea” campaign featuring celebrity stylist and E! TV personality Brad Goreski. The 300mg single-dose pre-filled pen for Dupixent is now available. MC2 Therapeutics is partnering with EPI Health on the commercialization of Wynzora Cream in the US.
A feasibility study in collaboration between LEO Innovation Lab, VisualDX, and the German Association of Dermatological Prevention supports technology to assist in diagnosis of skin conditions. Leo Pharma’s investigational JAK inhibitor delgocitinib cream is Fast Tracked by the FDA for the potential treatment of adults with moderate-to-severe chronic hand eczema. Two new studies reinforce the efficacy and safety of Dupixent for the treatment of atopic dermatitis in children and adults. Stelara is now approved for pediatric patients, 6-11 years of age, with moderate to severe plaque psoriasis. Look for Rihanna’s new Fenty Skin line under the umbrella of skincare offerings.
The vast majority of dermatologists around the world—95.6 percent—believe climate change is occurring, and 88 percent think it will impact the incidence of skin diseases, according to the first international survey of dermatologists on the topic, conducted online by the International Society of Dermatology's Climate Change Committee. FDA has approved MC2 Therapeutics Wynzora Cream for once-daily topical treatment of plaque psoriasis in adults. Tremfya is the first IL-23 inhibitor FDA-approved for active psoriatic arthritis. AbbVie's upadacitinib met both primary and all secondary endpoints in Measure Up 2, the second Phase 3 study in individuals with moderate to severe atopic dermatitis.
Research Identifies Long-Term Benefits of Incorporating Ceramides into Baby Skincare
EADV Congress Update: Insights on Psoriasis, AD, UV Protection, COVID-19, and More
DermWireTV: Sanofi Genzyme & Regeneron Global AD Report; Hydroquinone; Pfizer NDA; VCS
Exclusive: Global Report Identifies Strategies for Improved Quality of Care in AD
FDA Grants Priority Review for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe AD
Connect Biopharma to Present Additional Positive Results from the Phase 1b Study of CBP-201 for Patients with Moderate-to-Severe AD at EADV Virtual Meeting
Eczema Missing Link Found: Researchers ID Protein that Triggers AD by Bacteria